To Explore The Effect Of Different Drugs In The Treatment Of Heart Failure On The Cardiac Function And Prognosis Of Patients

Objective:To investigate the effects of conventional therapy(ACEI/ARB),neoactive,sakubitril-valsartan and sakubitril-valsartan and neoreactive combination on cardiac function and prognosis of patients with heart failure,and to analyze and explore the relationship between soluble growth hormone expression gene 2 protein(s ST-2)expression level and heart failure.Methods:All 120 heart failure patients who met the criteria and were hospitalized in the cardiology ward of Shanxi Provincial People’s Hospital from 2021 to 2022 were selected as study subjects,and general data such as age,sex,past history,blood pressure,and personal history were recorded after admission,and patients were given fasting venous blood for laboratory tests of routine blood,blood lipids,s ST2,NT-pro-BNP levels,liver and kidney in the early morning of the second day of admission.On the second day of admission,the patient was given fasting blood for biochemical indexes such as routine blood,lipids,s ST2,NT-pro-BNP level,liver and kidney function,and cardiac ultrasound to record the left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left atrial end-systolic diameter(LAD),and peak mitral flow in early diastole/maximum mitral flow in late diastole(E/A).The patients were followed up 6months after discharge and the results of blood biochemical indexes and cardiac ultrasound were recorded.The patients were grouped according to the medication used during hospitalization and follow-up,including 28 cases in the conventional treatment(ACEI/ARB)group,30 cases in the neoreactive group,30 cases in the sakubitril-valsartan group,and 32 cases in the neoreactive and sakubitril-valsartan combination treatment group.The treatment effect of each group was evaluated by blood biochemical indexes,degree of symptom relief and cardiac ultrasound indexes.Results:There were no statistically significant differences in general data,past history,personal history,blood biochemical indexes,cardiac ultrasound indicators,etc.in the combination treatment group of conventional treatment(ACEI/ARB),natriuretic peptide group,sacubitril valsartan group,etc.all four treatment groups can improve left ventricular ejection fraction(LVEF)in heart failure patients,and can reduce left ventricular end-diastolic diameter(LVEDD)and NT-pro-BNP levels,but compared with the four groups,The treatment effect of natriuretic peptide and sacubitril-valsartan was more significant,and the difference was statistically significant(P<0.05).Soluble growth stimulating factor gene expression of 2 protein(s ST2)decreased significantly after the increase of left ventricular ejection fraction(LVEF)in patients with heart failure,and was negatively correlated with LVEF,and the difference was statistically significant(P<0.05).Conclusion:ACEI/ARB,natriuretic peptide,sakubitril-valsartan,natriuretic peptide and ARNI can improve LVEF,NT-pro-BNP levels and ventricular remodeling in patients with heart failure,but the combination treatment of natriuretic peptide and ARNI is more effective.s ST2 is an independent risk factor for heart failure and is inversely associated with ejection fraction.